Introduction
The number of suitable radiometals for use in nuclear medicine (both in diagnosis and in therapy) is considerable (gemitters like 111 In or 67 Ga; positron emitters as 68 Ga or 64 Cu, and particle emitters like 90 Y, 177 Lu (b-emitter) or 213 Bi (aemitter)). [1] [2] [3] [4] However, the central question in the development of new radiopharmaceutical agents is how to deliver them specifically to the cellular targets (receptors). Many strategies have been attempted and some are currently in clinical use. The general strategy in the field of gammaimaging is based on the use of radio-labeled conjugates that bind to specific receptors that are overexpressed in certain regions or organs in the body. Specific carriers like monoclonal antibodies [5] and peptides [6] proved, so far, to be the most successful approaches. The moiety of the conjugate that encapsulates the radio metal is a bifunctional chelator which simultaneously presents a functionality (usually carboxylic and amine groups) suitable for covalent binding to the carrier agent.
Magnetic resonance imaging (MRI) is a diagnostic modality based on the enhancement of contrast given by paramagnetic contrast agents (CAs). Gadolinium(iii) chelates demonstrated to be the most suitable paramagnetic CAs for MRI, due to the high paramagnetism of the Gd III ion (4f 7 ) and to its slow electron spin relaxation. The efficiency of a MRI CA is based on its ability to selectively reduce the water proton relaxation times of normal and lesioned tissues in the body, and is expressed by its relaxivity, r 1 (in units of mm À1 s
À1
). The relaxivity is defined as the longitudinal relaxation rate enhancement of the water protons for 1 mm concentration of paramagnetic compound. [7, 8] Nowadays molecular imaging is a field of fast rising interest. [9] The main requisites in molecular imaging using MRI are high relaxivity and high biospecificity, in order to deliver [ 1 as many paramagnetic species as possible to the receptors of interest and thus obtain images of the targeted cells.
For the detection of hepatic lesions there are a few hepatocyte-specific MRI CAs which are lipophilic or amphiphilic compounds: [Gd(BOPTA)(H 2 O)] 2À (BOPTA = 4-carboxy-5,8,11-tris(carboxymethyl)-1-phenyl-2-oxa-5,8,11-trazatridecan-13-oic acid), [10] [Gd(EOB- [11] [Mn(dpdp)(H 2 , [12] superparamagnetic iron oxides, [13] liposomal [14] and micellar [15] paramagnetic systems. The focus of our ongoing research plan is the synthesis of multivalent glycoconjugates of metal complexes as potential agents for medical imaging (MRI and scintigraphy). These compounds include two different moieties: a metal chelator capable of forming chelates with lanthanide(iii) ions with high kinetic and thermodynamic stability, and a sugar moiety capable of interacting with high affinity and selectivity with endogenous lectins. [16] Lectins are a large group of carbohydrate binding proteins broadly found in nature (including plants, animals and lower organisms). The lectin-carbohydrate interaction controls many biological events (immune function, fertilization, infectious cycles, metastasis, etc.). [17] The effect of the valence of synthetic and natural glycoconjugates on the affinity to lectins has been fully demonstrated, although the physical nature of the phenomenon is still debatable.
[18] A critical feature in the glycoconjugatelectin interaction is the topology of both the glycoconjugate and lectin. In this respect, the relative orientation and spacing of the carbohydrate residues in the glycoconjugate in relation to the distribution of the Carbohydrate Recognition Domains (CRDs) on the lectins is of fundamental importance. [18, 19] The hepatocyte cells on liver express lectins that recognize terminal b-galactosyl residues on desilylated glycoproteins-asialoglycoprotein receptor (ASGPR). [20] The targeting of endogenous lectins for drug delivery is an appealing concept. [21] The ASGPR can be targeted by attaching galactose residues to a desired carrier containing efficient reporter groups. [22] [23] [24] [25] [26] The pioneering work of Lee and others has demonstrated that the order of increasing affinity (in vivo and in vitro) of multivalent glycoconjugates for the ASGPR is tetra > tri > di > mono. [52] The targeting of the ASGPR has been demonstrated both in a cell line and mice with a 111 In-radiolabelled galactopyranosyl conjugate of DOTA (1,4,7,10-tetrakis(carboxymethyl)-1,4,7,10-tetraazacyclododecane). [27] 99m
Tc-DTPA-GSA, a conjugate of galactosylated serum albumin (GSA) with 99m Tc-DTPA (DTPA = 3,6,9-tris(carboxymethyl)-3,6,9-triazaundecan-1,11-dioic acid), is useful in SPECT (single photon emission computed tomography) hepatic imaging to assess ASGPR in mice [28] and used clinically in humans. [29, 30] Monocrystalline iron oxide nanoparticles (MION) conjugated to the bovine plasma protein asialofetuin (ASF), (MION-ASF), [31] arabinogalactan (AG)-coated ultra-small superparamagnetic iron oxide particles (USPIO), (AG-USPIO), [32, 33] spin-labelled arabinogalactan, [34] and a Gd-DTPA conjugate of polylysine (PL) derivatized with galactosyl groups (Gd-DTPA-gal-PL), [35] have also been developed as potential contrast agents for liver MRI by targeting the hepatocyte ASGPR and tested in cells and mice.
In this paper we report the synthesis and characterization of a series of multivalent lanthanide(iii)-glycoconjugates, based on DOTA-monoamide functionalized chelators ( Figure 1 ). DOTA-like chelators are well known to form Ln III chelates of high thermodynamic and kinetic stability, which is of crucial importance for in vivo applications. [36] The covalent binding of Gd III chelates to macro and biomolecules [7, 8] and the formation of supramolecular assemblies [15] have been reported to slow down the tumbling rate of the paramagnetic chelates which leads then to higher relaxivities. In the present work, the in vitro relaxivity of the Gd III -glycoconjugates was measured and the parameters that influence relaxivity were determined. We hypothesised that the glycoconjugates-lectin association could substantially slow down the rotation and therefore enhance proton relaxivity of the Gd III -labelled glycoconjugates. This could be the basis of a new class of paramagnetic CAs targeted to lectins, both soluble and membrane-bound. In order to test this concept we studied the interaction of Gd III -glycoconjugates in vitro with the model lectin Ricinus communis agglutinin (RCA) through relaxometric measurements. To our knowledge this is the first time that the interaction between a Gd III -glycoconjugate and a lectin is experimentally investigated in the context of MRI.
Results and Discussion
Synthesis of the ligands: We devised the synthesis of a series of glycoconjugates of metal complexes, which includes various galactose (Gal), glucose (Glc) and lactose (Lac) derivatives of different valencies, namely the monoderivatives 1 (DOTAGal, DOTAGlc, DOTALac), the divalent glycoconjugates 2 (DOTAGal 2 , DOTAGlc 2 , DOTALac 2 ) and the tetravalent glycoconjugate 3 (DOTAGal 4 ) (Figure 1) .
We have devised a convergent synthesis for these ligands. A metal chelator block and a sugar block suitably functionalised were synthesised separately. Subsequent coupling afforded the fully protected glycoconjugates, which were then deprotected to give the final compounds 1, 2 and 3.
The metal pro-chelator block 7 is a protected amino-functionalized DOTA monoamide derivative (Scheme 1).
As sugar block we used a carboxylic acid-functionalised glycodendrimer, prepared as illustrated for generation 1 (G1) dendromers 10 [37] (Scheme 2). Generation 2 (G2) dendromer 12 was prepared in a convergent way from diamine 9 and TFA salt 11 a (Scheme 3).
The synthesis of diamine 9 was accomplished by a modification of Roys original procedure [37] (Scheme 4). The standard DCC/HOBt (DCC = dicyclohexylcarbodiimide; HOBt = 1-hydroxybenzotriazol) coupling procedure revealed successful for preparing fully protected monovalent 18, divalent 17 and tetravalent 16-glycoconjugates. A twostep deprotection, TFA/CH 2 Cl 2 followed by KOMe/EtOH, afforded the fully deprotected monovalent 1, divalent 2 and tetravalent 3 glycoconjugates (Schemes 5 and 6). [19, 37] High resolution mass spectrometry (HRMS) confirmed the identity of the final compounds. In all cases, changing the pH did not affect the sugar proton resonances, but had a profound effect on the DOTA macrocyclic and pendant arm CH 2 signals. The CH 2 signals from all pendant arms except one remained sharp throughout the pH range, as well as the signals from the macrocyclic CH 2 protons, which are very broad below pH 3, due to the rigidifying effect of the presence of internal hydrogen bonds. [38] These signals sharpen considerably and shift to low frequencies as the pH increases above 3.0, due to successive selective deprotonation of some of the nitrogens and carboxylate oxygens, destroying most of those internal hydrogen bonds. A temperature increase has a similar sharpening effect on those resonances.
The CH 2 resonances of the bridging moieties are generally sharp, indicating flexibility, and have almost no pH dependence, with some exceptions. In DOTAX 2 (X = Gal, Glc and Lac) and in DOTAGal 4 , the NCH 2 C(O) proton signals shift somewhat (eg. from 4.06 ppm at pH 1.1 to 4.12 ppm at pH 5.2, for DOTAGlc 2 ) but broaden and disappear at pH > 5.5, while some broadening is also observed for the NCH 2 protons close to the branching protonated nitrogen atoms. This indicates that an interaction occurs at high pH between these positively charged nitrogens and the negatively charged deprotonated DOTA-monoamide pendant carboxylate groups. [40, 41] The Eu III -DOTALac 2 complex shows two sets of signals corresponding to M-and m-type structures, with a relative intensity ratio of about 3:1 (Figure 2) , similar to what has been found for other assymetric DOTA derivatives. [42] The paramagnetic centers are expected to cause a separate resonance for each of the protons of each isomer in the assymetrically substituted amide ligand, with a total of 24. All of these are seen for the M isomer, in the + 33.5 to À16.6 ppm range, but only some for the m isomer, for example, at ppm À8.8, À7.2, À6.0, À1.2. A comparison of the relative shifts of the M isomer of Eu III -DOTALac 2 and Eu III -DOTA [43] allows the assignment of the resonances of this isomer to the types of protons present in the DOTA moiety of the glycoconjugate (ppm: À16.6, À15.5, À15.0, À14.8 for ac 2 ; À14.6, À12.5, À12.1, À11.4 for ax 2 ; À10.6, À7.9, À7.6, À6.8 for ac 1 ; À5.6, À4.8, À3.1, À2.9 for eq 2 ; À1.9, À0.1, 0.0, + 1.9 for eq 1 , + 31.1, + 31.4, + 32.6, + 33.5 for ax 1 , Figure 2 ). In the present case, the orientation of the substituent did not lead to a doubling of these resonances as a consequence of the formation of two structural isomers, indicating that fast rotation about the amide bond occurs, similar to what has been found for other monosubstituted amide derivatives, but not in disubstituted ones. [42] The signals are somewhat broadened at 25 8C due to M$m isomeric exchange, [41] but this exchange broadening effect is much more noticeable for the Sm III complexes, where only six broad resonances are detectable at + 7.2, + 4.2, + 1.6, + 1.4, + 1.2 and À2.1 ppm, which, when compared with those of Sm III -DOTA, [40] can be assigned, respectively, to the ac 2 , ax 2 , ac 1 , eq 1 , eq 2 and ax 1 protons of the M isomer. However, this broadening causes overlap of the four signals from each type of proton in the four chelate units, and does not allow observation of the m isomer.
NMRD studies of the Gd
III -glycoconjugates and their binding to RCA: The proton relaxivity of the Gd III complexes describes the efficiency of the magnetic dipolar coupling between the water proton nuclei and the paramagnetic metal ion, therefore it is a direct measure of the efficacy of the complex as a contrast agent. The paramagnetic ion enhances the relaxation rates of the bulk water protons by long-range and short-range interactions (outer sphere and inner sphere relaxation, respectively). The inner sphere term is governed by the exchange rate of the inner sphere water molecule (k ex ), the rotational correlation time of the complex (t R ), and the longitudinal and transverse electronic relaxation rates of the Gd III (1/T 1e and 1/T 2e ). The outer sphere contribution to the overall proton relaxivity depends on the electron spin relaxation rates and the diffusion coefficient for the diffusion of a water proton away from a Gd III complex (see Appendix). [43] The proton relaxivities have been measured for the Gd III glycoconjugates of the three types of sugars at three different temperatures (25, 37 and 60 8C) between 0.2 and 20 MHz proton Larmor frequency. They are all characteristic of low molecular weight Gd III complexes. As a representative example we show the nuclear magnetic relaxation dispersion (NMRD) profiles of the divalent glucose derivative Gd III -DOTAGlc 2 ( Figure 3 ). The NMRD curves of the two divalent derivatives of galactose and lactose, Gd III -DOTAGal 2 and Gd III -DOTALac 2 , respectively, can be found in the supporting information. The profiles have been fitted to the usual Solomon-Bloembergen-Morgan theory that relates the paramagnetic relaxation rates to the microscopic parameters of the Gd III complex (for equations see Appendix). As it has been pointed out previously, given the large number of factors influencing proton relaxivity, the parameters describing relaxivity cannot be determined exclusively from the often featureless NMRD profiles. Therefore an independent access to some of the parameters is usually required. Water exchange rates have been determined on numerous Gd
2À and their different amide derivatives. As a relatively general rule, it was found that the replacement of each carboxylate coordinating group of the poly(amino carboxylate) ligand by an amide function results in a decrease of the water exchange rate by a factor of 3-4.
[ 43] This decrease is independent of the substituents on the amide group. The glycoconjugates studied here are all monoamide derivatives of DOTA 4À . Therefore, based on the large body of available data on the water exchange on similar DOTA-monoamides, in the analysis of the NMRD profiles we fixed the rate as well as the activation enthalpy of the water exchange to usual values (k ex 298 = 1.2 10 6 s À1 and DH°= 30.0 kJ mol
À1
). Moreover, the diffusion coefficient for the diffusion of a water proton away from a Gd III chelate (D GdH 298 ) as well as its activation energy is not much dependent on the nature of low molecular weight complexes; hence in the fitting procedure these two parameters were also fixed to common values. [44] Consequently, in the analysis of the NMRD profiles we fitted the rotational correlation time, t R , its activation energy, E R , and the parameters describing the electron spin relaxation, that is, the trace of the square of the transient zero-field-splitting (ZFS) tensor, D 2 , and the correlation time for the modulation of the ZFS, t v . The parameters obtained for the three Gd III chelates are presented in Table 1 .
The rotational correlation times calculated for the different glycoconjugates are all reasonable for small chelates, and as expected, increase with increasing molecular weight from the galactose and glucose derivatives to the larger size lactose conjugates. [43] As t R values dominate the high-field NMRD values, the relaxivities of these complexes at 20 MHz and 25 8C are significantly higher than those previously found for smaller DOTA-monoamide complexes. [42, 43, 45] The parameters obtained for the electron spin relaxation of the Gd III complexes are also within the usual range for similar Gd III -DOTA monoamide chelates, with a significant increase of D 2 relative to the more symmetric Gd III -DOTA chelate, affecting the low-field NMRD values. [42, 43, 45, 46] Although in the last few years it has become evident that the simplified model of electron spin relaxation used here is not fully adequate to describe Gd III chelates, [47] the application of the novel theories requires EPR data in a large field range which was beyond the scope of the present study.
The proton relaxivities of these small molecular weight chelates are limited by fast rotation. This is clearly shown by the temperature dependence of the profiles: proton relaxivities increase when the temperature decreases, thus the rotation slows down.
These glycoconjugates are capable of binding to lectins. In a solid phase competitive assay (ELLA, enzyme-linked lectin assay) we were able to verify a mini glycoside cluster effect in the binding of these glycoconjugates to PNA (peanut agglutinin). [18, 48] The binding could considerably decrease the tumbling rate of the Gd III -glycoconjugates and thus enhance their proton relaxivity. We have performed proton relaxivity measurements in solutions of the Gd III -glycoconjugates in the presence of Ricinus communis agglutinin, RCA 120 (M W = 120 000) as model lectin. RCA 120 is a S-S dimer of two subunits. Each subunit (M W = 60 000) is a heterodimeric protein made of two S-S linked chains, A and B chains. The B chain is made of two globular domains, with a carbohydrate binding site, specific for terminal b-linked galactosides, per domain. The A chain has N-glycosidase activity which inhibits protein synthesis. The two subunits are associated covalently by a SÀS bond between the two A chains. The dimer is further stabilised by contacts on the interface. [16, 17] Under the best available experimental conditions, the concentration of the RCA 120 was 0.5 %, corresponding to a 0.04 mm concentration (more concentrated solutions are not commercially available), whereas the concentration of the Gd III chelate was 1.0 mm (at lower concentrations of the paramagnetic species the relaxivity measurements become imprecise). Assuming an association constant of 10 4 [16] and two independent binding sites on the RCA molecule, and that the spacing of the sugar terminals on the divalent glycoconjugates does not allow the simultaneous clustering of both sugars on the same molecule of RCA, in the best case scenario we would have two Gd-glycoconjugate units per RCA molecule, that is, maximum 8 % of all the Gd III chelate would be bound to the protein. For all our systems we observed a slight increase (around 5 %) in proton relaxivity in a solution of 0.5 % RCA 120 . This relaxivity increase is not much higher than the error margin of the measurements, therefore we prefer not to interpret this result unambigously in terms of lectin binding. Although the bound species very likely has a higher proton relaxivity due to slower rotation, its concentration is too low and therefore a substantial increase in relaxivity is difficult to observe. A clear effect of the glycoconjugate-lectin association on the in vitro proton relaxivity could only be observed with considerably higher concentrations of the lectin-bound Gd III complex. The only possibility to increase the percentage of bound Gd-species, and therefore the relaxivity, is to have a higher concentration of lectin in the assay, however the lectin availability is a limiting factor. The feasibility of in vivo MRI applications based on receptor binding in general depends on the concentration of the given receptor as well as on the relaxivity of the receptor-bound species. Targeted receptors in cells in general are usually present at concentrations within the range 10 À9 -10 À13 mol g À1 of tissue. [49] The minimal concentration of a contrast agent that is detectable by MRI (the concentration necessary to observe a signal enhancement) has been estimated between 5 10 À7 mol g À1 for the low molecular weight Gd(HP-DO3A)(H 2 O) (r 1 = 3.7 mm À1 s
) and 1.9 10 À10 mol g À1 for a 6th generation, Gd(DTPA)-loaded dendrimer (r 1 = 5800 mm À1 s
per dendrimer) or 1.6 10 À11 mol g À1 for superparamagnetic iron oxide particles (r 2 = 72 000 mm À1 s À1 per particle) (HP-DO3A = 1,4,7-tris(carboxymethyl)-10-hydroxypropyl-1,4,7,10-tetraazacyclo-dodecane). [50] In addition to receptor binding on the cell surface, receptor mediated endocytosis can lead to accumulation of the magnetic species inside the cell. With an efficient internalization mechanism, the concentration of the MRI contrast agent inside the cell can largely exceed what is expected solely by surface binding, thus it can help circumvent the problem of low MRI sensibility. Preliminary results of biodistribution studies with Wistar rats using 153 Sm-labeled glycoconjugates of different valencies and sugar type indicate a specific hepatic uptake of the galactose and (to a less extent) lactose glycoconjugates through the ASGPR (results to be published separately). However, the feasibility of MR imaging based on the specific hepatic uptake of the Gd III glycoconjugates remains to be tested.
Conclusions
Conjugating a small glycodendrimer ending with galactose unit(s) to a DOTA scaffold via an amide bond generates a new class of stable hydrophilic glycoconjugates. The glycodendrimer architecture was found suitable to vary the sugar type and valence in an interactive way from a reduced number of building blocks.
The Ln III chelates of these glycoconjugates have predominant square antiprismatic solution structures of the coordinating DOTA moiety, with one inner-sphere water molecule. The flexibility of the glycodendrimer moiety in solution somehow limits the relaxivity of their Gd III complexes to values lower than expected from their molecular weight. However we envisaged that the lectin-glycoconjugate interaction could considerably slow down the tumbling rate and therefore increase the relaxivity of the Gd III chelates. Further studies are needed in order to unambiguously verify this effect. Our results open the way for the study of Gd IIIglycoconjugates as potential candidates for lectin-mediated molecular imaging agents.
Experimental Section
Materials and analysis: Chemicals were purchased from Sigma-Aldrich and used without further purification. Solvents used were of reagent grade and purified by usual methods. Reactions were monitored by TLC
charring with 10 % sulphuric acid in ethanol. Flash chromatography was performed on Kieselgel 60 (Merck, 230-400 mesh). The relevant fractions from flash chromatography were pooled and concentrated under reduced pressure, T < 40 8C. FAB mass spectra (positive mode) were recorded using a VG Autospec mass spectrometer with 3-nitrobenzyl alcohol (NBA) as matrix. 13 C NMR spectra were proton broad-band decoupled using a decoupling scheme. The pD of the D 2 O solutions was adjusted with DCl or CO 2 -free NaOD and converted to pH values using the isotopic correction pH pD-0.4. The pD values were measured on a HANNA pH meter with a HI1310 combined electrode (HANNA instruments, Italy). Synthesis of orthogonally alkylated cyclen (6): K 2 CO 3 (9.43 g, 68.3 mmol) was added to a solution of monoalkylated cyclen 5 (2.94 g, 11.4 mmol) in MeCN (100 mL). To this suspension a solution of tert-butylbromoacetate (6.66 g, 34.1 mmol) in MeCN (30 mL) was added dropwise over 20 minutes. The suspension was vigorously stirred at room temperature for 4 h. The suspended solid was removed by filtration, the solvent was evaporated under reduced pressure, and the residue was purified by dry flash chromatography (100 % CH 2 
(C(O)).
Synthesis of divalent peracetylated thioglycosides 10 a-c: Typical procedure illustrated for 10 a: To a solution of bis-amine 9 (0.95 g, 3.87 mmol) in ice-cooled dichoromethane (100 mL) was sequentially added peracetylated (galactosylthio)propionic acid 8 a (3.55 g, 8.13 mmol), HOBt (1.23 g, 9.76 mmol) and DCC (1.67 g, 9.76 mmol) were added dropwise as a solution in dicloromethane (10 mL). After 15 minutes the reaction mixture was removed from the ice bath and allowed to reach room temperature. The reaction mixture was further stirred at room temperature overnight. The precipitate dicyclohexylurea (DCU) was removed by filtration and washed with dichloromethane. The filtrate was concentrated under reduced pressure to give thick syrup. The compound was taken into ethyl acetate (200 mL) and sequentially washed with NaHCO 3 (sat. sol.; 3 100 mL) and brine (100 mL). The organic phase was concentrated under reduced pressure to give a white foam. Purification by dry flash chromatography (100 % CH 2 Cl 2 !MeOH/CH 2 Cl 2 1:1) afforded the title compound as a white foam (4.02 g, 96 %). 1 H NMR analysis revealed the disappearance of the signal at d = 1.47 assigned to the tertbutyl group. No further purification or characterisation was carried out (we assumed a 100 % yield on the deprotection reaction). The product was dissolved in ice-cooled CH 2 Cl 2 (10 mL) and titrated (pH paper) to pH 9-10 with DIPEA. To this solution was added a solution of deprotected bis-amine 9 (0.146 g, 0.595 mmol) in CH 2 Cl 2 (10 mL), followed by HOBt (0.220 g, 1.49 mmol) and a solution of DCC (0.300 g, 1.49 mmol) in CH 2 Cl 2 (10 mL) was added dropwise. The resulting mixture was stirred for 15 minutes while cooled on an ice bath, allowed to reach room temperature and further stirred for 24 h. The precipitated DCU was removed by filtration and the solvent was removed under reduced pressure. The resulting oil was redissolved in ethyl acetate (200 mL) and washed with NaHCO 3 (sat. sol.; 3 50 mL) and brine (50 mL). The solvent was removed under reduced pressure, and the residue was purified by dry flash chromatography (100 % CH 2 Cl 2 !20 % EtOH/CH 2 Cl 2 ) to give the title compound as a white foam (1.12 g, 83 %). Synthesis of fully protected monovalent glycoconjugates 18 a-c: Typical procedure illustrated for 18 a: A round-bottomed flask was charged with ethylenediamine-functionalised cyclen 7 (0.375 g, 0.61 mmol), peracetylated galactosylthiopropionic acid 8 a (0.292 g, 0.67 mmol) and HOBt (0.100 g, 0.67 mmol) in CH 2 Cl 2 (20 mL). The reaction was initiated by adding dropwise a solution of DCC (0.140 g, 0.67 mmol) in CH 2 Cl 2 (5 mL). The reaction mixture was stirred while cooled on an ice bath for 15 minutes, allowed to reach room temperature and further stirred for 16 h. The precipitate DCU was filtered off, the filtrate was concentrated under reduced pressure and the resulting yellow foam was redissolved in EtOAc (100 mL). The organic phase was washed sequentially with KHCO 3 (sat. sol. 3 50 mL) and brine (50 mL) and concentrated under reduced pressure to give a white foam. The product was purified by dry flash chromatography (100 % CH 2 Cl 2 !30 % MeOH/CH 2 Cl 2 ) to give the title compound as a white foam (0.580 g, 92 %). 8 H) , 4.53 (d, J = 9.9 Hz, 2 H; H-1'), 4.59 (d, J = 9.9 Hz, 2 H; H-1), 4.92 (t, J = 9.9 Hz, 2 H; H-2), 4.95 (m, 2 H; H-3'), 5.07 (dd, J = 7.8, 2. Preparation of Ln III -glycoconjugates for NMR: The Ln III -glycoconjugates were prepared by adding a slight excess (1.1 equiv) of an aqueous solution of LnCl 3 to an aqueous solution of the glycoconjugate. The solution was slowly adjusted to pH 5 with aq. KOH and stirred at 70 8C for 8 h. The final pH was adjusted to 7 with KOH (aq) and any precipitate was filtered off. The solution was concentrated and purified by gel filtration with Sephadex G10, eluting with water. The relevant fractions were pooled and freeze dried to afford the Ln III complexes.
H NMR (300 MHz
Preparation of Gd III -glycoconjugates for NMRD: The 1/T 1 nuclear magnetic relaxation dispersion (NMRD) profiles of the water protons at 25, 37 and 60 8C were obtained on 2.52-4.63 mm Gd III solutions. The concentration of the Gd III solutions was determined by ICP. The concentration of the DOTA-derivated glycoconjugates was determined from the pHpotentiometric titration curves in the presence of a 50-fold excess of CaCl 2 , with TMAOH. The solutions of the Gd III -glycoconjugates were prepared by adding appropriate quantities of the glycoconjugates to an aqueous solution of gadolinium perchlorate (3-5 % glycoconjugate excess). The Gd III -glycoconjugate solutions were freeze dried and diluted with 25 mm phosphate buffer (pH 7.4). The Gd III concentrations were verified by ICP measurement.
